HYCAMTIN Drug Patent Profile

« Back to Dashboard

When do Hycamtin patents expire, and when can generic versions of Hycamtin launch?

Hycamtin is a drug marketed by Sandoz and is included in two NDAs.

The generic ingredient in HYCAMTIN is topotecan hydrochloride. Seven suppliers are listed for this compound. Additional details are available on the topotecan hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Hycamtin

A generic version of HYCAMTIN was approved as topotecan hydrochloride by FRESENIUS KABI USA on November 29^th, 2010.

Summary for HYCAMTIN

US Patents:	0
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for HYCAMTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981-001	Oct 11, 2007		RX	Yes	No
Sandoz	HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981-002	Oct 11, 2007		RX	Yes	Yes
Sandoz	HYCAMTIN	topotecan hydrochloride	INJECTABLE;INJECTION	020671-001	May 28, 1996	AP	RX	Yes	Yes

International Patents for HYCAMTIN

See the table below for patents covering HYCAMTIN around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	143368
Australia	2639488
Australia	612735
Canada	1308102	ANALOGUES HYDROSOLUBLES DE LA CAMPTOTHECINE (WATER SOLUBLE CAMPTOTHECIN ANALOGS)
China	1027265
China	1034724
China	1035380

Supplementary Protection Certificates for HYCAMTIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0321122	SPC/GB96/057	United Kingdom		PRODUCT NAME: TOPOTECAN; REGISTERED: CH IKS-NR:53857 19961016; UK EU/1/96/027/001 19961112; UK EU/1/96/027/002 19961112
0321122	2/1997	Austria		PRODUCT NAME: TOPOTECAN; NAT. REGISTRATION NO/DATE: EU/1/96/027/001 EU/1/96/027/002 19961112; FIRST REGISTRATION: LI 53857 01 19961016
0321122	C970017	Netherlands		PRODUCT NAME: TOPOTECAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARD BAAR ZOUT, HYDRAAT OF SOLVAAT, IN HET BIJZONDER HET HYDROCHLORI DE; NAT. REGISTRATION NO/DATE: EU/1/96/027/001 - EU/1/96/027/002 19961112; FIRST REGISTRATION: CH IKS 53857 19961016
0321122	97C0009	Belgium		PRODUCT NAME: TOPOTECAN HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: EU/1/96/027/001 19961112 ; FIRST REGISTRATION: CH 53857 19961016

HYCAMTIN (Topotecan) Investment Scenario and Fundamentals Analysis

Last updated: April 23, 2026

Hycamtin (topotecan) is a late-stage oncology product with established clinical use in small cell lung cancer (SCLC) and ovarian cancer. The investment thesis is shaped by patent and exclusivity status in key markets, competitive intensity from other topoisomerase inhibitors and newer regimens, and the payer landscape for single-agent chemotherapy. Fundamentals hinge on whether the product can defend share in label indications while manufacturers and distributors maintain uninterrupted supply and pricing stability.

What is HYCAMTIN and how is it used clinically?

Hycamtin is topotecan, a topoisomerase I inhibitor. In the U.S., it is marketed for:

• Ovarian cancer: treatment of women with recurrent ovarian cancer after platinum-based therapy (label wording varies by formulation and current label version).
• Small cell lung cancer: treatment of relapsed SCLC in patients who are refractory to or progressed after platinum-based chemotherapy (label wording varies by current label version).

Core mechanism positioning for investment: it is a line-of-therapy chemotherapy product used when disease has recurred or progressed after prior platinum-based treatment, and in refractory relapse settings where treatment options can be limited.

How do patents and exclusivity define the investment risk?

The investment risk for branded HYCAMTIN comes from two vectors:

1. Direct generic entry in major markets for topotecan hydrochloride injection and related formulations.
2. Indication and lifecycle management risks if regulatory exclusivity has expired and price competition accelerates.

A strict fundamentals assessment requires current, jurisdiction-specific patent mapping (compound, formulation, method of use, and any pediatric exclusivity extensions) and the active status in each country. Without complete, up-to-date legal status for topotecan and the exact Hycamtin product family in each jurisdiction, a definitive patent-expiration-driven model cannot be produced.

What does demand look like and what drives revenue?

For chemotherapy agents like topotecan, demand depends on:

• Incidence and recurrence patterns in ovarian cancer and SCLC
• Treatment sequencing: how often clinicians use single-agent topotecan after platinum failure
• Access and reimbursement: formularies, prior authorization, and oncology infusion economics
• Competitive substitution: off-label chemotherapy choices, other approved agents, and clinical guideline shifts

Revenue drivers for investment modeling:

• Net price and reimbursement intensity in oncology
• Dose intensity (patient weight, dosing schedule adherence, real-world treatment duration)
• Product availability: any supply disruptions tend to shift oncologist behavior temporarily and can lead to longer-term switching

How competitive intensity impacts pricing and share

Topotecan faces competition across chemotherapy and oncology drug classes:

• Within chemotherapy: other cytotoxic regimens used in relapsed ovarian cancer and relapsed SCLC
• Across mechanisms: later-line targeted and immune strategies where relevant
• Biosimilar and nonproprietary substitution: where approved generics exist, branded pricing typically compresses

Investment implication: for mature products with generic pressure, valuation rests more on defended share and supply reliability than on growth levers.

What do clinical and guideline trends imply?

Clinical practice evolves along two axes that matter for topotecan:

• Guideline inclusion: continued recommendation in relapsed/refractory settings supports baseline use
• Trial outcomes: if newer regimens demonstrate better overall survival or response quality, topotecan can lose share to regimens that move earlier in the line of therapy

Investment implication: topotecan’s addressable market is narrower than for frontline regimens. Under stable guideline positions, revenue tends to behave like a declining mature asset rather than a growth story, unless new approvals expand use.

What are the key manufacturing and supply fundamentals?

For injectable oncology products:

• Supply continuity drives treatment persistence
• Batch release and quality affect distribution stability
• Second-source strategy reduces stockout risk

Investment implication: the risk premium in mature injectables usually sits in supply reliability and working capital impact rather than in clinical trial uncertainty.

How should investors model financial outcomes?

A practical fundamentals model for Hycamtin should use:

• Net sales sensitivity to:
  • average selling price (ASP) compression after generic competition
  • patient volumes in ovarian cancer and SCLC relapse
  • channel mix and utilization management
• Gross margin sensitivity to:
  • input costs (API and sterile manufacturing)
  • manufacturing yields and compliance overhead
• Operating leverage sensitivity to:
  • SG&A and distribution costs in oncology specialty channels

Because no current market share, pricing, or channel utilization numbers are provided here, a complete financial forecast cannot be computed from the available information in this prompt.

Where does value accrue in the Hycamtin ecosystem?

Value accrues in three places:

• Ongoing demand from relapsed indications where topotecan remains standard or accepted practice
• Contracted reimbursement that limits price collapse even when generics are present
• Operational execution: supply reliability and consistent patient access

Where value declines:

• Formulary substitution as alternative agents become preferred
• Stronger price competition that pushes net price down faster than volumes can compensate

Investment scenario: base case vs. downside case

Base case (defense, not expansion)

• Stable label use in relapsed ovarian cancer and relapsed SCLC
• Continued payer acceptance but with ongoing net price pressure
• Supply continuity supports utilization

Expected characteristics: mature-asset behavior with modest revenue drift, margin compression from pricing and mix.

Downside case (faster share and price erosion)

• Increased competitive substitution and accelerated generic-driven pricing
• Formulary changes reduce uptake in specific payer segments
• Any supply disruption causes longer-term switching to alternative chemotherapy

Expected characteristics: sharper declines in net sales and margin, and higher churn risk in oncology accounts.

Upside case (narrow)

• Reaffirmed guideline position in additional subgroup definitions that preserve dosing utilization
• Stabilized net pricing through contracting or competitive equilibrium
• Improved supply throughput and lower COGS per dose

Expected characteristics: less downside than base case; limited growth.

Key diligence checkpoints for investors

1. Legal status by country for the exact marketed dosage form(s), including:
   • active patents, method/formulation patents, and any exclusivity periods
2. U.S. channel pricing:
   • current ASP trends, average discount levels, and payer coverage pattern stability
3. Utilization evidence:
   • usage per oncology setting, line-of-therapy distribution, and persistence after switch
4. Supply reliability and manufacturing capacity:
   • batch release performance and continuity risk in sterile production
5. Competitive landscape mapping:
   • approved alternatives, typical sequencing, and oncology formulary behavior

Key Takeaways

• Hycamtin (topotecan) is a mature oncology chemotherapy product whose investment profile is dominated by patent/exclusivity status, generic and payer-driven pricing pressure, and supply reliability.
• Demand is supported by relapse settings in SCLC and ovarian cancer, but revenue growth depends on maintaining position against chemotherapy alternatives and regimen sequencing shifts.
• The investment decision should be anchored in jurisdiction-specific patent mapping and current net pricing/utilization data, because generic substitution and formulary changes can outsize volume effects.
• For financial modeling, the most sensitive levers typically are net price compression, dose volume retention, and gross margin from sterile manufacturing economics.

---

FAQs

1) Is HYCAMTIN a growth stock or a mature-asset business?

Hycamtin behaves like a mature-asset oncology chemotherapy. Without evidence of new exclusivity or expansion, the realistic profile is defense with price pressure rather than durable growth.

2) What indications drive Hycamtin demand?

In the U.S., demand concentrates on relapsed settings in ovarian cancer after platinum therapy and relapsed SCLC after prior platinum-based chemotherapy.

3) What is the biggest commercial risk for investors?

Commercial risk is pricing and share erosion driven by generic competition and payer formulary substitution, which can reduce net sales faster than volumes can offset.

4) What operational risks matter most for injectable oncology products?

For sterile injectables, investors should focus on supply continuity, batch release performance, sterile manufacturing capacity, and compliance overhead.

5) What due diligence should be done before underwriting?

Investors should validate current patent and exclusivity status by jurisdiction, confirm net pricing trends by channel, and review utilization and persistence behavior in payer and provider settings.

---

References (APA)

[1] U.S. Food and Drug Administration. (n.d.). Hycamtin (topotecan) prescribing information. FDA.